MD Anderson and Guardant Health announce partnership to make comprehensive liquid biopsy part of oncology standard of care
The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment. The commercial, research and development agreement will make MD Anderson among the few hospitals in the world with integrated comprehensive liquid biopsy (CLB) capabilities.
While standard biopsies are considered...
MD Anderson and Deerfield Management create Vescor LLC to develop novel therapeutics based on inhibiting autophagy for treatment of specific cancers
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by...